ZVIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ZVIA is not a good buy right now for an impatient trader. The setup lacks a proprietary buy signal, the short-term pattern stats skew bearish (next week bias), and insider selling has surged. With price still below the key pivot (1.941) and momentum not decisively turning up, the odds favor more chop-to-down before a cleaner entry appears.
Price closed at 1.88 (up ~1.65% vs prior close 1.82) but remains below the key pivot at 1.941, meaning the stock is still in a "below-pivot" posture. Support sits near S1=1.803 (then S2=1.719); resistance is R1=2.079 (then R2=2.163). RSI(6) ~38.95 is weak/near oversold-leaning but not a clear reversal signal. MACD histogram is positive (0.0188) but "positively contracting," suggesting bullish momentum is fading rather than accelerating. Moving averages are converging, consistent with consolidation and no clean trend. Pattern-based projection also leans negative (-3.44% next week). Net: weak-to-neutral trend with downside risk unless it reclaims and holds above 1.941.
Category tailwinds: multiple news items highlight growth in functional/low-sugar beverages, which supports Zevia’s long-term narrative.
Upcoming earnings (QDEC 2025 on 2026-02-26 after hours) can act as a catalyst if results/guide surprise positively.
Call-skewed options open interest (low put/call) suggests some bullish positioning.
Insider activity: insiders are selling, with selling amount up ~1223.8% over the last month—strongly negative near-term signal.
Technical posture is below pivot resistance (1.
with fading MACD momentum and bearish pattern stats (next-week downside bias).
Margin pressure: gross margin declined YoY, which can weigh on valuation and earnings quality.
News flow provided is mostly broad industry/other-company items (limited direct, company-specific upside catalyst for Zevia).
Latest reported quarter: 2025/Q3. Revenue grew to $40.84M (+12.31% YoY), showing continued top-line expansion. Net income improved to -$2.69M (loss narrowed ~6.29% YoY), indicating incremental progress toward profitability, and EPS was -$0.04 (flat YoY). The key negative is gross margin falling to 45.09% (-6.51% YoY), implying cost/incentive pressure that can offset revenue growth. Overall: growth is positive, losses are narrowing slowly, but profitability quality is pressured by declining margins.
No analyst rating or price-target change data was provided, so a recent trend in Wall Street ratings/targets cannot be assessed from the dataset. Based on the available data only, pros would cite revenue growth and category tailwinds; cons would emphasize margin compression, ongoing losses, and heavy insider selling.
